Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Tarceva Effective in Asians with Specific Form of Lung Cancer

publication date: Jun 8, 2010
In a Phase II trial, Roche’s Tarveca greatly increased survival among patients with a specific form of non-small cell lung cancer (NSLC), advanced lung adenocarcinoma. The drug was especially potent among patients who have epidermal growth factor receptor (EGFR) activating mutations. NSLC with EGFR activating mutations is a genetically distinct form of lung cancer that is most common in patients who have never smoked, patients with adenocarcinoma, people of Asian origin and females. More details...

Stock Symbol: (SVX: ROG)


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital